http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9902752-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8e95d5b6b71220515f3878c5f799c0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 |
| filingDate | 2013-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3534e1cb40987f9125776f9b56b8a6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7e53249d0ba62d05313e199c0dc9e06 |
| publicationDate | 2018-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9902752-B2 |
| titleOfInvention | 5-fluorouracil derivatives |
| abstract | The present invention is directed to a compound that can be used in the treatment of cancer. The compound is represented by formula (I) n nFurther, X isn n nIn addition, R 1 is selected from H,n n nandn nsubstituted or unsubstituted cyclic terpene moieties; R 7 and R 8 are independently selected from C 1 to C 30 alkyl; n is an integer ranging 1 to 4; and a is an integer ranging from 1 to 20. Moreover, R 2 is H; a Mono-phosphate, Di-phosphate, Tri-phosphate or phosphoamidite moiety; or —Y—X 1 or —Y-L-Y 1 —X 1 , where Y and Y 1 are independently from each other a single bond or a functional connecting moiety, X 1 is a colloid-active compound, a fluorescence marker, or a polynucleotide moiety having up to 50 nucleotide residues. L is a linker where Y and X 1 are covalently linked together; R 5 and R 6 represent independently from each other a C 1 -C 28 -alkyl moiety which may optionally be substituted/interrupted by one or more heteroatom(s) and/or functional group(s); a C 1 -C 28 -alkyl moiety substituted with one or more moieties selected from the group —Y—X 1 or —Y-L-Y 1 —X 1 ; form a ring having at least 5 members, wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s); or R 5 and R 6 represent independently from each other —Y—X 1 or —Y-L-Y 1 —X 1 ; with the provisos that R 1 and R 2 are not both H and the compound comprises at least two chains each of which having 4 or more carbon atoms. |
| priorityDate | 2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2749.